J8560 Insurance Policy Changes

Iclusig® (ponatinib) (Revised)

Humana revised its Iclusig® (ponatinib) prior authorization policy effective April 22, 2026. The policy maintains strict prior authorization requirements for three indications: chronic phase CML (requires failure on 2+ TKIs or T315I mutation), accelerated/blast phase CML (requires no other kinase inhibitors available or T315I mutation), and Ph+ ALL (requires no other kinase inhibitors, T315I mutation, or use with chemotherapy). All approvals exclude members with disease progression on Iclusig. Billing teams must ensure prior authorization is obtained before dispensing for any of these indications.